Contrasting the Brain Effects of Risperidone and Invega With Functional Magnetic Resonance Imaging (fMRI) and Positron Emission Tomography (PET) Scanning
NCT ID: NCT00937261
Last Updated: 2010-10-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE4
96 participants
INTERVENTIONAL
2009-07-31
2011-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Risperdal
Risperdal 2-8mg per day
Risperidone
2mg - 8mg per day, for the duration of participation in the study
Invega
Invega 6-12mg per day
Paliperidone
6mg - 12mg per day, for the duration of participation in the study
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Risperidone
2mg - 8mg per day, for the duration of participation in the study
Paliperidone
6mg - 12mg per day, for the duration of participation in the study
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* are diagnosed with schizophrenia
* are able to provide written informed consent
* can safely have an MRI
Exclusion Criteria
* have participated in another drug study in the past 28 days
* are pregnant or trying to become pregnant or are breastfeeding
* are colorblind
* have a history of alcohol, cannabis, or cocaine abuse within two weeks prior to the study
* have a current or past history of a major medical illness or have abnormal lab values which the study doctor feels is significant
* certain medications are also exclusionary including aripiprazole.
18 Years
60 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Janssen, LP
INDUSTRY
University of California, Irvine
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
UC Irvine -FBIRN
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Steven G Potkin, M.D.
Role: PRINCIPAL_INVESTIGATOR
UC Irvine
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
UC Irvine
Irvine, California, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Steven G Potkin, M.D.
Role: primary
Liv McMillan, B.S.
Role: backup
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
BIRN 2008-6382
Identifier Type: -
Identifier Source: org_study_id